
WHAT IS CLAIMED IS:

1. A pharmaceutical composition, comprising:

a compound of formula (I):



(I)

or a pharmaceutically acceptable salt thereof, and

a cyclodextrin,

wherein

 represents a double bond in Z or E configuration;

R^1 is selected from the group consisting of hydrogen, halogen, nitro, cyano, hydroxyl, amino, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, and heteroalknyl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, and heteroalknyl is optionally substituted with one or more R^a;


R^2 is $-C(O)R^b$;

R^3 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalknyl, saturated or partially unsaturated cycloalkyl, saturated or partially unsaturated heterocyclyl, aryl, and heteroaryl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is optionally substituted with cyano, halogen, hydroxyl, amino, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, or heteroalkynyl;

L is selected from the group consisting of a direct bond, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalknyl, saturated or partially unsaturated cycloalkyl, saturated or partially unsaturated heterocyclyl, aryl, and heteraryl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl,

heteroalkenyl, heteroalknyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is optionally substituted with one or more R^f;

W is selected from the group consisting of:



wherein the * end of W is connected to L;

R^4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalknyl, saturated or partially unsaturated cycloalkyl, saturated or partially unsaturated heterocyclyl, aryl, and heteraryl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is optionally substituted with cyano, halogen, hydroxyl, amino, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl;

each of R^a is independently selected from the group consisting of hydrogen, halogen, hydroxyl, amino, cyano, nitro, or $-NR^cR^d$;

R^b is selected from the group consisting of hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalknyl, saturated or partially unsaturated cycloalkyl, saturated or partially unsaturated heterocyclyl, aryl, heteraryl, $-NR^cR^d$ and $-OR^e$;

each of R^c and R^d is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, and heteroaryl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl and heteroaryl is optionally substituted with cyano, halogen, hydroxyl, or amino;

R^e is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, saturated or partially unsaturated cycloalkyl, saturated or partially unsaturated heterocyclyl, aryl, and heteroaryl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl，heterocyclyl, aryl and heteroaryl is optionally substituted with cyano, halogen, hydroxyl, amino, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, or heteroalkynyl;

each of R^f is independently selected from the group consisting of hydrogen, cyano, halogen, hydroxyl, amino, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, saturated or partially unsaturated cycloalkyl, saturated or partially unsaturated heterocyclyl, aryl, and heteroaryl; or

two R^f together with the atom to which they are both attached, form saturated or partially unsaturated cycloalkyl, or saturated or partially unsaturated heterocyclyl, wherein each of cycloalkyl and heterocyclyl is optionally substituted with cyano, halogen, hydroxyl, amino and alkyl;

R^g is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, saturated or partially unsaturated cycloalkyl, saturated or partially unsaturated heterocyclyl, aryl, and heteroaryl, wherein each of hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is optionally substituted with cyano, halogen, hydroxyl, or amino;

n is 0, 1, 2, 3, 4 or 5.

2. The pharmaceutical composition according to claim 1, wherein the cyclodextrin is β-cyclodextrin;

preferably, the β-cyclodextrin is sulfobutyl ether-β-cyclodextrin, cyclobutyl alkyl ether-β-cyclodextrin, or hydroxypropyl-β-cyclodextrin.

3. The pharmaceutical composition according to any one of claims 1-2, wherein the pharmaceutical composition is a solution;

optionally, the solution comprises 0.1-10 mg/mL, 0.2-10 mg/mL, 0.3-5 mg/mL, 0.4-2 mg/mL, 0.5-1 mg/mL, or 0.6-0.9 mg/mL of the compound or the pharmaceutically acceptable salt thereof;

optionally, the solution comprises 20-400 mg/mL, 30-300 mg/mL, 40-300 mg/mL, 50-250 mg/mL, 60-200 mg/mL, 70-150 mg/mL, or 80-100 mg/mL of the cyclodextrin;

optionally, the weight ratio of the cyclodextrin to the compound or the pharmaceutically acceptable salt thereof is 50:1 to 400:1, 50:1 to 300:1, 50:1 to 250:1, 60:1 to 250:1, 70:1 to 200:1, 80:1 to 150:1, or 90:1 to 120:1, wherein the weight of the pharmaceutically acceptable salt of the compound is based on the weight of the compound contained therein;

optionally, the pharmaceutical composition further comprises a buffer;

preferably, the buffer is an acidic buffer;


preferably, the acidic buffer is selected from phosphoric acid, hydrochloric acid, succinic acid, acetic acid, tartaric acid, lactic acid, citric acid, malic acid, glycolic acid, or hydrates thereof;

preferably, the acidic buffer is citric acid monohydrate;


preferably, the solution comprises 1-3 mg/mL, 1-2.5 mg/mL, or 1-2 mg/mL of citric acid monohydrate.

4. The pharmaceutical composition according to claim 3, wherein the pharmaceutical composition has a pH of 3-4.


5. The pharmaceutical composition according to any one of claims 1-4, wherein the compound has a formula selected from the group consisting of:




(II),




(III),




(IV),




(V),




(VI),




(VII),




(VIII),




(IX),




(IIa),




(IIIa),




(IVa),




(Va),




(VIa),




(VIIa),




(VIIIa),




(IXa),




(IIb),




(IIIb),




(IVb),




(Vb),




(VIb),



(VIIb),




(VIIIb), and




(IXb).

6. The pharmaceutical composition according to claim 5, wherein ~~~~ is a double bond in Z configuration, and/or R^1 is halogen and n is 1.













7. The pharmaceutical composition according to any one of claims 1-6, wherein the compound has a formula selected from the group consisting of:























,



,












,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,

,

,

,

,










and

;

preferably, the compound is:



.

8. A method for preparing the pharmaceutical composition according to any one of claims 1-7, comprising:

mixing the cyclodextrin with water to form a first mixture;

optionally, adding a buffer to the first mixture to form a second mixture;

adding an acidic pH adjuster to the second mixture to adjust the pH to 1-1.5, thereby forming a third mixture;

adding the compound or the pharmaceutically acceptable salt thereof to the third mixture to form a fourth mixture;

adding a basic pH adjuster to the fourth mixture to adjust the pH to 3-4, thereby forming a fifth mixture; and

optionally, adding water for injection to the fifth mixture to form the pharmaceutical composition;

optionally, the method further comprises lyophilizing the pharmaceutical composition to form a lyophilized composition.

9. The pharmaceutical composition according to any one of claims 1-7 for use in treating a vascular disease in a subject in need thereof;

preferably, the vascular disease is selected from atherothrombosis, ischemia, stroke, cerebral thrombosis, arterial thrombosis, thrombotic cerebrovascular diseases, cardiovascular diseases, and blood clot.

10. The pharmaceutical composition according to any one of claims 1-7 for use in inhibiting platelet aggregation in a subject in need thereof.